
Sep 18, 2026 · 2h 12m
Australia’s psychedelic breakthrough offers advocates a regulatory playbook
#883: How to Legalize Medical Psychedelics in Your Country — Tania de Jong on The Playbook Behind Australia's World-First Breakthrough
The episode shows how coalition-building, clinical credibility, and persistent regulator engagement turned restricted psychedelic prescribing into Australian policy.
- 1Mind Medicine Australia built a national coalition of clinicians, scientists, volunteers, and political allies around MDMA and psilocybin access.
- 2Australia’s framework remains open-ended, with therapist restrictions, bureaucratic barriers, and high treatment costs limiting practical access.
- 3Psychedelic therapy depends on preparation, clinical context, integration, and sustained follow-up rather than pharmacology alone.
Don't miss
Tania explains how Mind Medicine Australia’s coalition-building and persistent communication with regulators helped convert a national campaign into restricted prescribing access.
The brief
Tania de Jong recounts how Mind Medicine Australia assembled clinicians, scientists, volunteers, and political allies to move MDMA and psilocybin toward controlled medical use.
The campaign’s unusual advantage was its breadth: local chapters, public submissions, clinician training, scientific advisers, personal outreach, and sustained engagement with regulators.
Australia’s breakthrough did not settle the harder questions. Therapist restrictions, open-ended rules, limited capacity, and months of labor-intensive care keep treatment expensive.
The conversation also resists psychedelic exceptionalism: outcomes depend on preparation, therapeutic relationship, integration, patient circumstances, and the durability of follow-up work.
The standout lesson is practical rather than mystical: regulatory change advances when advocacy remains persistent without sacrificing scientific credibility or clinical realism.
What was said on this episode
36 statements · 27 positive · 6 negative · 3 neutral
Australia became the first country to permit prescribed MDMA and psilocybin for psychiatric conditions in 2023.
“in 2023 made Australia the first country in the world to allow MDMA and psilocybin to be prescribed for psychiatric conditions.”
Listen at 0:19
Australia’s psychedelic-medicine positioning could help many people.
“if Australia could start to position itself in this space, that there might be a chance to heal a lot of people”
Listen at 12:45
Over 98% of public submissions supported rescheduling MDMA and psilocybin in Australia.
“over 98% of people supported the rescheduling of these medicines. And this was the largest amount of public submissions ever received by regulators for rescheduling any medicines.”
Listen at 16:03
Mind Medicine Australia has trained more than 750 clinicians.
“we've already trained now over 750 clinicians”
Listen at 22:24
Australia rescheduled MDMA and psilocybin on February 3, 2023.
“in February, February 3rd, it was 2023. We're standing in the kitchen and my husband goes, it's been rescheduled.”
Listen at 42:43
Australia has over 20 psychedelic clinics and has treated roughly 400 patients.
“there's now over 20 clinics around Australia, mostly led by clinicians that we have trained through our certificate in psychedelic-assisted therapies. And over 400 patients or so roughly have been treated.”
Listen at 44:51
Australian psychedelic-assisted treatments are producing 60–80% remission rates.
“we are seeing 60 to 80% remission rates in Australia”
Listen at 46:57
Australian psychedelic-assisted therapy clinics report remission rates of 60–80%.
“we are seeing 60 to 80% remission rates in Australia, which is replicating what we've seen in trials around the world.”
Listen at 46:57
No serious adverse events have occurred among the reported Australian treatments.
“And there's been no serious adverse events.”
Listen at 47:13
Australian psychedelic treatments are approximately 70% MDMA and 30% psilocybin.
“it's probably about a 70/30 split.”
Listen at 47:59
Psychedelic-assisted therapy should not use a uniform cookie-cutter treatment model.
“we don't believe that there should be a cookie-cutter approach.”
Listen at 51:52
Australia may treat about 5,000 patients with these medicines within three years.
“maybe 5,000 is a realistic number”
Listen at 53:50
Australia may treat approximately 5,000 patients with psychedelic medicines within three years.
“maybe 5,000 is a realistic number.”
Listen at 53:50
No serious adverse events have been reported to Australia’s TGA.
“this is what can show the government— well, firstly, they know there's been no adverse events, serious ones, because there's been nothing reported to the TGA.”
Listen at 57:26
Reported psychedelic remission rates exceed those of existing PTSD treatments.
“these remission rates around 60 to 80%, that's compared against 10 to 15% for existing treatments for PTSD”
Listen at 57:37
Psychedelic treatments could generate substantial lifetime healthcare cost savings.
“There could be some serious cost savings here. We could save millions, tens of millions, hundreds of millions of dollars over the course of a patient's lifetime.”
Listen at 58:02
Australian public and private payers are funding psychedelic treatments for eligible patients.
“we now have the Department of Veterans Affairs who are supporting treatments for veterans. We have the National Disability Insurance Scheme also funding treatments. And we have Medibank, which is our largest health insurer, who have basically said that any eligible gold members of Medibank can get pretty much the whole treatment cost paid apart from a couple of thousand dollars.”
Listen at 58:20
Psilocybin combined with Syrian rue can suit appropriate clients.
“I think it's a great protocol for the right clients.”
Listen at 1:02:32
Syrian rue may amplify psilocybin experiences two- to tenfold.
“it expanded the visuals and the whole experience between 2 to 10 times”
Listen at 1:03:53
Psilocybin microdosing may relieve cluster headaches and migraines.
“A lot of people I know use psilocybin to microdose to remove their cluster headaches and their migraines.”
Listen at 1:09:49
Group psychedelic sessions and integration may offer important benefits.
“there is also something very much to be said for doing this in groups”
Listen at 1:12:02
Antidepressant remission rates do not increase over time like psychedelic-treatment rates can.
“that is not something that would ever happen with an antidepressant”
Listen at 1:25:00
Psychedelic-treatment remission can increase with effective integration work.
“in this case you have those 2 or 3 doses maximum, then you're having the psychotherapy and your remission is increasing if you engage well with the integration sessions”
Listen at 1:25:13
Psychedelic treatments should use careful screening, supervision, and integration.
“we believe that these treatments should be done in very careful ways”
Listen at 1:30:08
Psychedelic-assisted treatments should be delivered with stringent clinical safeguards.
“these treatments should be done in very careful ways”
Listen at 1:30:09
Video monitoring could eventually allow one clinician to supervise a psychedelic treatment session.
“There could be an argument in the future that says that one clinician with a patient, if there's a video there as well, might be sufficient.”
Listen at 1:30:53
One Australian psychedelic treatment including screening costs about A$8,000.
“So it starts at about $8,000 Australian dollars, which is about $5,000, let's say, US dollars, for one treatment including the screening.”
Listen at 1:32:51
One Australian psychedelic treatment costs about A$8,000 including screening.
“it starts at about $8,000 Australian dollars, which is about $5,000, let's say, US dollars, for one treatment including the screening”
Listen at 1:32:52
A three-to-four-month psychedelic treatment course may cost up to A$25,000.
“It's about a 3 to 4 month course that is costing maybe up to about about $25,000 Australian dollars”
Listen at 1:33:24
Most psychedelic treatment costs come from therapist time rather than the medicine.
“the majority of that cost is therapeutic time, like the medicine.”
Listen at 1:34:28
Ketamine treatment generally requires repeated use in most cases.
“the problem about ketamine is that it needs to be used over and over in most cases.”
Listen at 1:38:59
Psilocybin products associated with Compass Pathways and USONA will likely gain registration soon.
“there's going to be huge shifts globally over the next few months and that there's going to be psilocybin probably through Compass Pathways and USONA will be registered.”
Listen at 1:47:50
A MAPS-related psychedelic medicine may receive approval after an executive order.
“I think that's going to come through as well, especially given that the president's given that executive order.”
Listen at 1:48:06
More countries are expected to follow Australia’s psychedelic regulatory model.
“a lot more countries hopefully are going to be following Australia”
Listen at 1:48:19
Many safe and effective medical options are currently unavailable to the public.
“a lot of safe and effective medical options are not available. They're being withheld from the public.”
Listen at 1:52:20
Mind Medicine Australia aims to raise A$2.5 million for patient access.
“our goal is to raise at the moment $2.5 million”
Listen at 1:55:03
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

